📢It's #ESMO election time! I am delighted to be nominated for ESMO Director of Education 😊 ALL the nominees are fantastic representing the global @myesmo.bsky.social community 🌍 🙏for all the good wishes Rules this year for social media so that's it from me! Now please vote 🗳️!
Lizzy Smyth
@lizzysmyth.bsky.social
Oncologist. Cancer Research 👩⚕️. Clinical Trials 🧬💊. Oxford Irish. #Oncsky
We've spent 2024 discussing RT trial results in gastroesophageal cancer. My radiation oncology mate Som helps me make sense of it all below... 2024 Top Story in Oncology: The Role of Radiotherapy in Operable Gastro-Oesophageal and Gastric Cancer — Time for Change prac.co/l/22cfph7u
2024 Top Story in Oncology: The Role of Radiotherapy in Operable Gastro-Oesophageal and Gastric Cancer — Time for Change
Written by Elizabeth Smyth MD Written by Somnath Mukherjee MD, MRCP, FRCR, FRCP
prac.co
When the Western really has to work (via DPhil student text) Good to see the old methods live on
Just published in #ESMOopen results from our trial of IO-naive patients with advanced kidney cancer with PD1/CTLA4 and PD1/LAG3! www.esmoopen.com/article/S205...
DEFINE_ME
esmoopen.com
Twitter, as we knew it, is gone, stained by new horrific algorithms that promote misinformation. 🦋 is a much better place for those interested in science. And it’s growing fast. Thanks @jamiedoggett for highlighting our efforts to rebuild a safe place for scientific discussion.
Bluesky or X: The role influential HCPs will play in ‘stay, go or double-up’ cannot be underestimated. With #ASH24 and #SABCS2024 just around the corner, this is an interesting moment for health conversation on socials. @ptarantinomd.bsky.social #MedTwitter #MedSky www.linkedin.com/pulse/role-h...
Good to see our protocol paper for DECIPHER in press at ESMO GO! ctDNA 🧬 after surgery will detect pts with HER2➕ gastroesophageal #cancer at high risk of recurring 🧬➕ receive TDxD instead of usual post-op chemo Hope to #cure some micrometastatic cancers 🙏 www.sciencedirect.com/science/arti...
Evaluating trastuzumab deruxtecan in patients with gastrooesophageal adenocarcinoma who are ctDNA and HER2 positive: DECIPHER
Operable gastrooesophageal adenocarcinoma (GOA) is treated with multimodality therapy which is curative in <50% of patients. Patients in the UK with o…
sciencedirect.com
Our latest in @naturecomms.bsky.social from @danafarber.bsky.social / @mskcc.bsky.social collaboration: AI to extract cancer outcomes in EMR! www.nature.com/articles/s41...
OS results of KN-522 out in @NEJM. Terrific news: adding pembro to neoadjuvant chemo for TNBC saves lives (5% 5-year Δ). Bad news: we’re stuck with giving 5 drugs to all patients with stage II-III TNBC, with permanent toxicity for many. Biomarkers, please! t.co/8S9YWOP1lr
Nice work from my (ex 😥) fellow @acammarota.bsky.social 👏👏 Examining PD-L1 expression in RCTs of chemo vs. chemo-ICI in operable GEA we show: ✅Strong link between PD-L1 and pathological response. ✖️ Less so OS .. www.esmogastro.org/article/S294... Looking forward to MATTERHORN next year!
PD-L1 as a response biomarker to chemotherapy plus immune checkpoint inhibitors in operable gastroesophageal adenocarcinoma: a meta-analysis of neoadjuvant clinical trials
Perioperative chemoimmunotherapy [i.e. chemotherapy plus immune checkpoint inhibitor (ICI) (ChT–ICI)] is an investigational treatment for operable gastroesophageal adenocarcinoma (GEA) with unclear ou...
esmogastro.org
www.nature.com/articles/s41... Sharing our latest review article to highlight the importance of appropriately developing combination strategies for immune checkpoint therapy. Grateful for working with 3 brilliant scientists: Sangeeta Goswami, Kristen Pauken & Linghua Wang
Next-generation combination approaches for immune checkpoint therapy - Nature Immunology
In this Review, Sharma and colleagues describe the current landscape of combination therapies and discuss requirements for the development of effective combination strategies.
nature.com
Regular abstracts from #SABCS24 are out! 3407 pages of new breast cancer discoveries. Find them here: sabcs.org/Portals/0/Do...
sabcs.org
ASCO annual meeting 2025 abstract submitter open - closes Jan 28th. To support global innovation in cancer research, payment waivers offered to 1st authors from low- & lower-middle-income countries (World Bank)! Apply for a waiver when you submit an abstract conferences.asco.org/am/abstract-...
ASCO Meetings
conferences.asco.org
Looking forward to seeing the other institutions & societies join too... I've been lobbying mine 🙂
Wow! Both @helloeacr.bsky.social and @theaacr.bsky.social are now on @bsky.app 🦋. #CancerResearch
NEW #Oncology: EGFR expression mediates resistance to T-DXd (EGFR overexpression ⬇️ HER2 homodimerization & HER2/ADC internalization) Combining with EGFR mAbs restored HER2/ADC trafficking & ⬆️ activity in nonclinical models #DrugDevelopment #OncoSky www.cell.com/cell-reports...
EGFR-directed antibodies promote HER2 ADC internalization and efficacy
Gupta et al. demonstrate that high EGFR expression mediates resistance to HER2 antibody drug conjugates (ADCs) including trastuzumab deruxtecan (T-DXd) by limiting HER2/ADC internalization. The additi...
cell.com
@valdesan.bsky.social to the rescue! Oncology Vol 1 and 2 starter packs (links included in the packs) go.bsky.app/UP8aWPd #medsky #oncsky #oncosky #oncology
Can we get one of those nifty “click to follow all of these profiles” for #oncosky #cansky? I’m thinking someone must being working on this…right? Or did I just volunteer myself? 😭 👉👃 #medsky
go.bsky.app/GKXp9Fy Happy Friday! Sharing oncology starter pack #2👇
November is gastric cancer awareness month and we are sharing updates in the field ⭐ At #ESMO24, we spoke with Jessie Elliott on long-term survivorship concerns of patients with esophageal and gastric cancer. 👉See the video below! 👈 https://buff.ly/48WQh5R #stcsm #gism
Long-term survivorship concerns of patients with esophageal and gastric cancer - VJOncology
Jessie Elliott, FRCS, PhD, Trinity St. James’s Cancer Institute, Dublin, Ireland, discusses the long-term survivorship concerns of patients with esophageal...
buff.ly
Right on time for #NANETS2024: the North American Neuroendocrine Tumor Society is on @bsky.app ! Lots of posts to come from the NET community over the next three days during the Annual Symposium taking place in #Chicago. @oncothor.bsky.social @cancertrials.bsky.social @halletjulie.bsky.social
🚨The exodus of #MedTwitter #OncSky to #BlueSky @bsky.app is fascinating. All the #Twitter birds are now flying freely in the Bluesky. 🐦💙 Will #Bluesky succeed where #Threads and #Mastodon struggled?#MedTwitterMigration #BlueSkySocial @oncoalert.bsky.social @tmprowell.bsky.social
❓ Should we switch chemotherapy for patients with gastroesophageal cancer after 3 months? ARMANI trial published in Lancet Oncol today ✔️ Patients who switched to 2L pac/ram after 3m of OxFU had ⬆️ PFS and OS than patients who continued 1L chemo ❌....but also ⬆️ hospital visits & toxicity.
This oncology starter pack below👇🏼 is worth a follow.. #findyourpeople #medsky
@lizzysmyth.bsky.social added you to this list. Please share and spread the word. go.bsky.app/GKXp9Fy
Inspired by the other amazing starter packs - here's one for cancer researchers! I tried to make this broad - from immunology to genomics to cell biology and so much more.. This list also includes organizations & institutes supporting cancer researchers 🧪🔬⚕️🩺 Hope its useful! go.bsky.app/FEoaJMc
👏 Great to see this published! VESTIGE is a negative randomised trial with an important lesson.. ➡️ Give adjuvant FLOT even when there's residual cancer after neoadjuvant chemo. 👀 Looking forward to the translational work annalsofoncology.org/article/S0923-…